Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Buy to Hold at Noble Financial today. The stock closed yesterday at $1.45 on volume of 487,000 shares, below average daily volume of 676,000.
In the past 52 weeks, shares of BioCryst Pharmaceuticals have traded between a low of $1.08 and a high of $5.95 and closed yesterday at $1.45, which is 34% above that low price. The 200-day and 50-day moving averages have moved 0.88% lower and 5.04% lower over the past week, respectively.
BioCryst Pharmaceuticals, Inc., a biopharmaceutical company, discovers and designs novel small-molecule pharmaceuticals using structure-based drug design. The Company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders. BioCryst's lead immunological drug program targets T-cell proliferative disorders.
Potential upside of 141.4% exists for BioCryst Pharmaceuticals, based on a current level of $1.45 and analysts' average consensus price target of $3.50. BioCryst Pharmaceuticals shares should first meet resistance at the 50-day moving average (MA) of $3.09 and find additional resistance at the 200-day MA of $3.89.
SmarTrend is monitoring the recent change of momentum in BioCryst Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of BioCryst Pharmaceuticals in search of a potential trend change.
Keywords: analyst upgrades/downgrades biocryst pharmaceuticals